Tamoxifen (Nolvadex, Soltamox) is the most widely prescribed breast cancer therapy in the world. Some even call it the "backbone" of breast cancer treatment. Even with all that fanfare, tamoxifen has ...

Tamoxifen is both the most widely prescribed drug for breast cancer and preventative therapy worldwide. It is a synthetic derivative of triphenylethylene but was originally screened in a drug ...

Tamoxifen has been used for several years to treat hormone receptor-positive types of breast cancer. This is due to its ability to competitively block estrogen binding to estrogen receptors, which ...

Tamoxifen is a medication that has been used to treat breast cancer for more than 30 years. Though linked to weight gain, most studies do not support the link. Tamoxifen is a type of hormone therapy ...

Tamoxifen has long been used in breast cancer, both in the adjuvant and preventive setting, but uptake and adherence are notoriously low, mainly because of adverse events. Using a much lower dose to ...

Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in situ (DCIS), but its use is limited by adverse effects. Lower doses may be effective, but benefit ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their overall risks ...

Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient's gut microbiome can impact how effective the treatment is. A new ...

The combination of phosphodiesterase type 5 inhibitors (PDE5is) and the selective estrogen receptor modulator tamoxifen ...

Overview: Tamoxifen is commonly used to treat certain types of breast cancer. It is also used to lower your risk of invasive breast cancer and keep some breast cancers from coming back. It blocks ...

We determined the effect of breast irradiation plus tamoxifen on disease-free survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative breast cancer. The rate of ...